Qing Lin

age ~51

from Vista, CA

Get Report

Also known as:

Qing Lim
Lin S Qing

Phone and address:: 1960 Hacienda Dr, Vista, CA 92081

Connected to:

Qing Lin Phones & Addresses

1960 Hacienda Dr, Vista, CA 92081
Oceanside, CA
1037 Decker St, El Cajon, CA 92020
Southgate, KY

Medicine Doctors

Qing Jennifer Lin

view source

Specialties:

Anatomic Pathology & Clinical Pathology

Work:

The Beth Pathology
201 Lyons Ave BLDG EL, Newark, NJ 07112
9739267307 (phone), 9737058301 (fax)

Jersey City Medical Center Pathology Laboratory
355 Grand St STE 3, Jersey City, NJ 07302
2019152486 (phone), 2019152377 (fax)

Education:

Medical School
Tianjin Med Univ, Tianjin City, Tianjin, China
Graduated: 1988

Languages:

English

Description:

Dr. Lin graduated from the Tianjin Med Univ, Tianjin City, Tianjin, China in 1988. She works in Jersey City, NJ and 1 other location and specializes in Anatomic Pathology & Clinical Pathology. Dr. Lin is affiliated with Jersey City Medical Center and Newark Beth Israel Medical Center.

Name / Title

Company / Classification

Phones & Addresses

Qing Lin

CHEN'S KING BUFFET, INC

Qing Hua Lin
Director, Treasurer

Decor Products International, Inc

Qing Lin
Managing

Sun Hing Buffet LLC
Restaurant · Eating Place

5140 Via Seville, Oceanside, CA 92056
1960 Hacienda Dr, Vista, CA 92081
7608063586

Resumes

Qing Lin

view source

Qing Di Lin

view source

Qing Lin

view source

Education:

Renmin University of China 2005 - 2009

Qing Lin

view source

Qing Lin

view source

Qing Lin

view source

Qing Lin

view source

Qing Lin

view source

Isbn (Books And Publications)

Gong Zuo Dao Zhi Ren Shen Sun Hai Pei Chang

view source

Author
Qing Lin

ISBN #
7801822250

License Records

Qing Lin

License #:

MT037840T - Expired

Category:

Medicine

Type:

Graduate Medical Trainee

Qing Lin

License #:

3336962 - Expired

Category:

Health Care

Issued Date:

Nov 25, 1998

Effective Date:

Jun 12, 2002

Expiration Date:

Apr 30, 2000

Type:

Registered Nurse

Us Patents

Amylin Family Peptides
view source
US Patent:

8114958, Feb 14, 2012
Filed:

Feb 11, 2005
Appl. No.:

10/589054
Inventors:

Christopher J. Soares - La Jolla CA, US
Michael R. Hanley - Corte Madera CA, US
Diana Y. Lewis - San Diego CA, US
David Geoffrey Parkes - Del Mar CA, US
Carolyn M. Jodka - Encinitas CA, US
Kathryn S. Prickett - Foster City CA, US
Soumitra S. Ghosh - San Diego CA, US
Christine Marie Mack - San Diego CA, US
Qing Lin - Getzville NY, US
Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA
International Classification:

C07K 19/00
C07K 14/435
A61K 38/16
A61P 3/04
US Classification:

530307, 530324, 514 49, 514 119, 514909, 536 234
Abstract:

The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

Methods For Treatment Using Amylin Family Peptides
view source
US Patent:

8598120, Dec 3, 2013
Filed:

Feb 1, 2012
Appl. No.:

13/364250
Inventors:

Christopher J. Soares - La Jolla CA, US
Michael R. Hanley - Corte Madera CA, US
Diana Y. Lewis - San Diego CA, US
David G. Parkes - Del Mar CA, US
Carolyn M. Jodka - Encinitas CA, US
Kathryn S. Prickett - Foster City CA, US
Soumitra S. Ghosh - San Diego CA, US
Christine M. Mack - San Diego CA, US
Qing Lin - Getzville NY, US
Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE
International Classification:

A61K 38/16
A61P 3/04
A61P 5/22
C07K 14/435
C07K 19/00
US Classification:

514 119, 435 697, 514 49, 514909, 530307, 530329, 536 234, 930 60
Abstract:

The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

Peptide-Peptidase-Inhibitor Conjugates And Methods Of Making And Using Same
view source
US Patent:

8598314, Dec 3, 2013
Filed:

Sep 26, 2008
Appl. No.:

12/680539
Inventors:

Soumitra S. Ghosh - San Diego CA, US
Josue Alfaro-Lopez - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Odile Esther Levy - San Diego CA, US
Qing Lin - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE
International Classification:

A61K 38/00
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00
US Classification:

530324, 530325, 530326
Abstract:

Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

Peptide-Peptidase Inhibitor Conjugates And Methods Of Using Same
view source
US Patent:

20090186817, Jul 23, 2009
Filed:

Mar 21, 2007
Appl. No.:

12/293389
Inventors:

Soumitra S. Ghosh - San Diego CA, US
Josue Alfaro-Lopez - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Odile Esther Levy - San Diego CA, US
Qing Lin - Buffalo NY, US
Christopher J. Soares - San Diego CA, US
Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA
International Classification:

A61K 38/22
C07K 2/00
C07K 14/575
US Classification:

514 12, 530300, 530324
Abstract:

Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

Composition And Methods For Treatment Of Congestive Heart Failure
view source
US Patent:

20100029554, Feb 4, 2010
Filed:

May 25, 2007
Appl. No.:

12/301199
Inventors:

Soumitra S. Ghosh - San Diego CA, US
Diana Y. Lewis - Los Angeles CA, US
Samuel Janssen - San Diego CA, US
Ved Srivastava - San Diego CA, US
Que Liu - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Qing Lin - Buffalo NY, US
Assignee:

Amylin Pharmaceuticals, Inc. - San Diego
International Classification:

A61K 38/16
C07K 14/00
A61P 3/00
A61P 9/00
US Classification:

514 12, 530324
Abstract:

Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also disclosed. Further provided are compositions and methods for the treatment and/or prevention of diabetes mellitus, hyperglycemia, insulin resistance and obesity, and for the reduction of food intake and suppression of appetite of subjects.

Peptide-Peptidase Inhibitor Conjugates And Methods Of Using Same
view source
US Patent:

20100292172, Nov 18, 2010
Filed:

May 21, 2010
Appl. No.:

12/785396
Inventors:

SOUMITRA S. GHOSH - SAN DIEGO CA, US
JOSUE ALFARO-LOPEZ - SAN DIEGO CA, US
LAWRENCE J. D'SOUZA - SAN DIEGO CA, US
ODILE ESTHER LEVY - SAN DIEGO CA, US
QING LIN - BUFFALO NY, US
CHRISTOPHER J. SOARES - SAN DIEGO CA, US
Assignee:

AMYLIN PHARMACEUTICALS, INC. - SAN DIEGO CA
International Classification:

A61K 38/17
C07K 14/575
C07K 14/46
A61K 38/22
A61P 1/00
A61P 9/00
US Classification:

514 213, 530324
Abstract:

Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

Soft Segmentation Based Rules Optimization For Zero Detection Loss False Positive Reduction
view source
US Patent:

20200342556, Oct 29, 2020
Filed:

Apr 25, 2019
Appl. No.:

16/395112
Inventors:

- Roseville MN, US
Qing Lin - San Diego CA, US
International Classification:

G06Q 50/26
G06Q 40/00
G06F 17/27
Abstract:

A system and method includes soft-segment based rules optimization that can mitigate the overall false positives while maintaining 100% true positive detection. The soft clustering allows real-time re-assignment of an account to a dominate archetype behavior, as well as rule optimization based on a logical order with more relaxation on thresholds for the most inefficient rules is performed within each archetype. The rule optimization provides false positive reduction compared to a baseline rule system. The method can be used to reduce false positives for any rule-based detection system in which the same true positive detection is required.

Peptide-Peptidase Inhibitor Conjugates And Methods Of Using Same
view source
US Patent:

20140371148, Dec 18, 2014
Filed:

Jun 18, 2014
Appl. No.:

14/307615
Inventors:

- San Diego CA, US
- Wilmington DE, US
Lawrence J. D'Souza - San Diego CA, US
Odile Esther LEVY - San Diego CA, US
Qing LIN - Buffalo NY, US
Christopher J. SOARES - San Diego CA, US
International Classification:

A61K 47/48
US Classification:

514 117, 530308, 530324, 514 97
Abstract:

Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

Lawyers & Attorneys

Qing Lin - Lawyer

view source

ISLN:

1000750480

Admitted:

2016

News

First Glimpses of the Neutrino Fog

view source

th experiments employ a multiton volume of liquid xenon. Qing Lin of the University of Science and Technology of China and member of the PandaX Collaboration says that the result is an extremely important validation of the experiment. Detecting such a rare signal proves our ability to detect a dark
Date: Nov 07, 2024
Category: Science
Source: Google

PandaX sets new constraints on the search for light dark matter via ionization signals

view source

"Currently, strong constraints exist for heavy mass dark matter candidates derived from null results in direct detection experiments using xenon detectors," Yue Meng, Qing Lin and Ning Zhou told Tech Xplore, on behalf of the PandaX collaboration. "However, traditional searches are not sensitive to l
Date: Jul 19, 2023
Category: Science
Source: Google